Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Authors:
- Sitanshu S. SinghSSSitanshu S. Singh
- Raul CalvoRCRaul Calvo
- Anju KumariAKAnju Kumari
- Rushikesh V. SableRSRushikesh V. Sable
- Yuhong FangYFYuhong Fang
- Dingyin TaoDTDingyin Tao
- Xin HuXHXin Hu
- Sarah Gray. CastleSCSarah Gray. Castle
- Saifun NaharSNSaifun Nahar
- Dandan LiDLDandan Li
- Emily MajorEMEmily Major
- Tino W. SanchezTSTino W. Sanchez
Open Access
- 30 August 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (12) , 1827-1841
Abstract
As tumor-associated macrophages (TAM) exercise a plethora of protumor and immune evasive functions, novel strategies targeting TAMs to inhibit tumor progression have emerged within the current arena of cancer immunotherapy. Activation of the mannose receptor 1 (CD206) is a recent approach that recognizes immunosuppressive CD206high M2-like TAMs as a drug target. Ligation of CD206 both induces reprogramming of CD206high TAMs toward a proinflammatory phenotype and selectively triggers apoptosis in these cells. CD206-activating therapeutics are currently limited to the linear, 10mer peptide RP-182, 1, which is not a drug candidate. In this study, we sought to identify a better suitable candidate for future clinical development by synthesizing and evaluating a series of RP-182 analogs. Surprisingly, fatty acid derivative 1a [RP-182-PEG3-K(palmitic acid)] not only showed improved stability but also increased affinity to the CD206 receptor through enhanced interaction with a hydrophobic binding motif of CD206. Peptide 1a showed superior in vitro activity in cell-based assays of macrophage activation which was restricted to CD206high M2-polarized macrophages. Improvement in responses was disproportionally skewed toward improved induction of phagocytosis including cancer cell phagocytosis. Peptide 1a reprogrammed the immune landscape in genetically engineered murine KPC pancreatic tumors toward increased innate immune surveillance and improved tumor control and effectively suppressed tumor growth of murine B16 melanoma allografts.Keywords
All Related Versions
Funding Information
- National Cancer Institute (ZIA BC 011267)
- National Center for Advancing Translational Sciences (1ZIATR000302)
This publication has 53 references indexed in Scilit:
- Peptide lipidation stabilizes structure to enhance biological functionMolecular Metabolism, 2013
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?Science, 2013
- Lactam-Stabilized Helical Analogues of the Analgesic μ-Conotoxin KIIIAJournal of Medicinal Chemistry, 2011
- Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α and growth arrest-specific gene 6Immunology, 2010
- T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune ResponsesThe Journal of Immunology, 2010
- Myristoyl-Based Transport of Peptides into Living CellsBiochemistry, 2007
- TNF-α Inhibits Macrophage Clearance of Apoptotic Cells via Cytosolic Phospholipase A2 and Oxidant-Dependent MechanismsThe Journal of Immunology, 2007
- Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription FactorsImmunity, 2006
- Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopyProceedings of the National Academy of Sciences, 2005
- The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesisJournal of Experimental Medicine, 2005